54 related articles for article (PubMed ID: 38444118)
21. Impact of Dapivirine and Placebo Vaginal Rings on the Microbiota of Adolescent, Lactating, and Postmenopausal Females.
Austin MN; Meyn LA; Avolia HA; Petrina MA; Cosentino LA; Alphonse C; Chen BA; Bunge K; Noguchi L; Beigi R; Squires K; Hillier SL
J Infect Dis; 2022 Jun; 225(12):2208-2218. PubMed ID: 34865071
[TBL] [Abstract][Full Text] [Related]
22. Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world.
Ridgeway K; Montgomery ET; Smith K; Torjesen K; van der Straten A; Achilles SL; Griffin JB
Contraception; 2022 Feb; 106():16-33. PubMed ID: 34644609
[TBL] [Abstract][Full Text] [Related]
23. Assessing the Burden of Infant Deaths Due to Herpes Simplex Virus, Human Immunodeficiency Virus, and Congenital Syphilis: United States, 1995 to 2017.
Slutsker JS; Schillinger JA
Sex Transm Dis; 2021 Aug; 48(8S):S4-S10. PubMed ID: 33967231
[TBL] [Abstract][Full Text] [Related]
24. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Blumenthal J; Jain S; He F; Amico KR; Kofron R; Ellorin E; Stockman JK; Psaros C; Ntim GM; Chow K; Anderson PL; Haubrich R; Corado K; Moore DJ; Morris S; Landovitz RJ
Clin Infect Dis; 2021 Oct; 73(7):1149-1156. PubMed ID: 33864370
[TBL] [Abstract][Full Text] [Related]
25. HIV Pre-exposure Prophylaxis Use and Persistence among Black Ciswomen: "Women Need to Protect Themselves, Period".
Pyra M; Johnson AK; Devlin S; Uvin AZ; Irby S; Stewart E; Blum C; Green M; Haider S; Hirschhorn LR; Ridgway JP
J Racial Ethn Health Disparities; 2022 Jun; 9(3):820-829. PubMed ID: 33733424
[TBL] [Abstract][Full Text] [Related]
26. Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis.
Griffin JB; Ridgeway K; Montgomery E; Torjesen K; Clark R; Peterson J; Baggaley R; van der Straten A
PLoS One; 2019; 14(11):e0224898. PubMed ID: 31703094
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
Keller MJ; Wood L; Billingsley JM; Ray LL; Goymer J; Sinclair S; McGinn AP; Marzinke MA; Frank B; Srinivasan S; Liu C; Atrio JM; Espinoza L; Mugo N; Spiegel HML; Anderson PL; Fredricks DN; Hendrix CW; Marrazzo J; Bosinger SE; Herold BC
Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
[TBL] [Abstract][Full Text] [Related]
28. Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States.
Chemaitelly H; Nagelkerke N; Omori R; Abu-Raddad LJ
PLoS One; 2019; 14(6):e0214151. PubMed ID: 31170140
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
[TBL] [Abstract][Full Text] [Related]
30. Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
Taneva E; Sinclair S; Mesquita PM; Weinrick B; Cameron SA; Cheshenko N; Reagle K; Frank B; Srinivasan S; Fredricks D; Keller MJ; Herold BC
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997295
[TBL] [Abstract][Full Text] [Related]
31. Impact of contraceptive initiation on vaginal microbiota.
Achilles SL; Austin MN; Meyn LA; Mhlanga F; Chirenje ZM; Hillier SL
Am J Obstet Gynecol; 2018 Jun; 218(6):622.e1-622.e10. PubMed ID: 29505773
[TBL] [Abstract][Full Text] [Related]
32. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis.
Looker KJ; Elmes JAR; Gottlieb SL; Schiffer JT; Vickerman P; Turner KME; Boily MC
Lancet Infect Dis; 2017 Dec; 17(12):1303-1316. PubMed ID: 28843576
[TBL] [Abstract][Full Text] [Related]
33. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
Klatt NR; Cheu R; Birse K; Zevin AS; Perner M; Noël-Romas L; Grobler A; Westmacott G; Xie IY; Butler J; Mansoor L; McKinnon LR; Passmore JS; Abdool Karim Q; Abdool Karim SS; Burgener AD
Science; 2017 Jun; 356(6341):938-945. PubMed ID: 28572388
[TBL] [Abstract][Full Text] [Related]
34. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
35. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
36. Metabolic signatures of bacterial vaginosis.
Srinivasan S; Morgan MT; Fiedler TL; Djukovic D; Hoffman NG; Raftery D; Marrazzo JM; Fredricks DN
mBio; 2015 Apr; 6(2):. PubMed ID: 25873373
[TBL] [Abstract][Full Text] [Related]
37. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
38. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
39. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy.
Clark JT; Clark MR; Shelke NB; Johnson TJ; Smith EM; Andreasen AK; Nebeker JS; Fabian J; Friend DR; Kiser PF
PLoS One; 2014; 9(3):e88509. PubMed ID: 24599325
[TBL] [Abstract][Full Text] [Related]
40. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.
Herold BC; Dezzutti CS; Richardson BA; Marrazzo J; Mesquita PM; Carpenter C; Huber A; Louissaint N; Marzinke MA; Hillier SL; Hendrix CW
J Acquir Immune Defic Syndr; 2014 May; 66(1):65-73. PubMed ID: 24457633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
